Logo image of VERO

VENUS CONCEPT INC (VERO) Stock Fundamental Analysis

NASDAQ:VERO - US92332W3034 - Common Stock

2.45 USD
+0.02 (+0.82%)
Last: 8/22/2025, 8:00:02 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to VERO. VERO was compared to 185 industry peers in the Health Care Equipment & Supplies industry. VERO has a bad profitability rating. Also its financial health evaluation is rather negative. VERO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VERO has reported negative net income.
In the past year VERO has reported a negative cash flow from operations.
VERO had negative earnings in each of the past 5 years.
VERO had a negative operating cash flow in each of the past 5 years.
VERO Yearly Net Income VS EBIT VS OCF VS FCFVERO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -78.10%, VERO is doing worse than 75.40% of the companies in the same industry.
Looking at the Return On Equity, with a value of -2191.20%, VERO is doing worse than 90.91% of the companies in the same industry.
Industry RankSector Rank
ROA -78.1%
ROE -2191.2%
ROIC N/A
ROA(3y)-47.85%
ROA(5y)-42.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VERO Yearly ROA, ROE, ROICVERO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 67.90%, VERO is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
VERO's Gross Margin has been stable in the last couple of years.
VERO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.88%
GM growth 5Y-0.33%
VERO Yearly Profit, Operating, Gross MarginsVERO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

1

2. Health

2.1 Basic Checks

VERO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VERO has more shares outstanding
The number of shares outstanding for VERO has been increased compared to 5 years ago.
VERO has a better debt/assets ratio than last year.
VERO Yearly Shares OutstandingVERO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K
VERO Yearly Total Debt VS Total AssetsVERO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

VERO has an Altman-Z score of -7.40. This is a bad value and indicates that VERO is not financially healthy and even has some risk of bankruptcy.
VERO's Altman-Z score of -7.40 is on the low side compared to the rest of the industry. VERO is outperformed by 71.66% of its industry peers.
VERO has a Debt/Equity ratio of 9.53. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 9.53, VERO is not doing good in the industry: 91.98% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 9.53
Debt/FCF N/A
Altman-Z -7.4
ROIC/WACCN/A
WACC3.17%
VERO Yearly LT Debt VS Equity VS FCFVERO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

VERO has a Current Ratio of 1.28. This is a normal value and indicates that VERO is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.28, VERO is not doing good in the industry: 79.14% of the companies in the same industry are doing better.
VERO has a Quick Ratio of 1.28. This is a bad value and indicates that VERO is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.79, VERO is doing worse than 88.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.28
Quick Ratio 0.79
VERO Yearly Current Assets VS Current LiabilitesVERO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.91% over the past year.
The Revenue for VERO has decreased by -15.09% in the past year. This is quite bad
VERO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.10% yearly.
EPS 1Y (TTM)44.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.07%
Revenue 1Y (TTM)-15.09%
Revenue growth 3Y-15.01%
Revenue growth 5Y-10.1%
Sales Q2Q%-5.37%

3.2 Future

Based on estimates for the next years, VERO will show a very strong growth in Earnings Per Share. The EPS will grow by 39.60% on average per year.
Based on estimates for the next years, VERO will show a decrease in Revenue. The Revenue will decrease by -1.32% on average per year.
EPS Next Y77.14%
EPS Next 2Y39.6%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-9.43%
Revenue Next 2Y-1.32%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VERO Yearly Revenue VS EstimatesVERO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
VERO Yearly EPS VS EstimatesVERO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -1K -2K -3K -4K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VERO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERO Price Earnings VS Forward Price EarningsVERO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERO Per share dataVERO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

VERO's earnings are expected to grow with 39.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.6%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

VERO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VENUS CONCEPT INC

NASDAQ:VERO (8/22/2025, 8:00:02 PM)

2.45

+0.02 (+0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners13.61%
Inst Owner Change-6.34%
Ins Owners0.78%
Ins Owner Change0%
Market Cap4.56M
Analysts45.71
Price TargetN/A
Short Float %4.02%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.71%
Min EPS beat(2)-21.43%
Max EPS beat(2)-9.99%
EPS beat(4)0
Avg EPS beat(4)-36.09%
Min EPS beat(4)-108.38%
Max EPS beat(4)-4.58%
EPS beat(8)1
Avg EPS beat(8)-26.39%
EPS beat(12)2
Avg EPS beat(12)-31.09%
EPS beat(16)4
Avg EPS beat(16)-23.24%
Revenue beat(2)0
Avg Revenue beat(2)-6.74%
Min Revenue beat(2)-9.08%
Max Revenue beat(2)-4.4%
Revenue beat(4)0
Avg Revenue beat(4)-8.14%
Min Revenue beat(4)-14.85%
Max Revenue beat(4)-4.24%
Revenue beat(8)1
Avg Revenue beat(8)-7.09%
Revenue beat(12)3
Avg Revenue beat(12)-5.37%
Revenue beat(16)5
Avg Revenue beat(16)-4.55%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.11%
EPS NY rev (1m)7.43%
EPS NY rev (3m)48.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)1.42%
Revenue NY rev (3m)-1.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.07
P/FCF N/A
P/OCF N/A
P/B 2.01
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-50.78
EYN/A
EPS(NY)-3.96
Fwd EYN/A
FCF(TTM)-7.87
FCFYN/A
OCF(TTM)-7.79
OCFYN/A
SpS32.79
BVpS1.22
TBVpS-1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.1%
ROE -2191.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.9%
FCFM N/A
ROA(3y)-47.85%
ROA(5y)-42.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.88%
GM growth 5Y-0.33%
F-Score4
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 9.53
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.44%
Cap/Sales 0.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.28
Quick Ratio 0.79
Altman-Z -7.4
F-Score4
WACC3.17%
ROIC/WACCN/A
Cap/Depr(3y)4.54%
Cap/Depr(5y)6.03%
Cap/Sales(3y)0.23%
Cap/Sales(5y)0.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.07%
EPS Next Y77.14%
EPS Next 2Y39.6%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.09%
Revenue growth 3Y-15.01%
Revenue growth 5Y-10.1%
Sales Q2Q%-5.37%
Revenue Next Year-9.43%
Revenue Next 2Y-1.32%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-3.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year67.6%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.11%
OCF growth 3YN/A
OCF growth 5YN/A